Vanda Pharmaceuticals | VNDA - Net Income


Vanda Pharmaceuticals reported $-18.9M in Net Income for its fiscal quarter ending in December of 2024.





Net Income Change Date
Acadia Pharmaceuticals USD 31.5M 27.86M Jun/2026
Agios Pharmaceuticals USD -99.11M 8.93M Mar/2026
Akebia Therapeutics USD -12.24M 12.78M Dec/2025
Alnylam Pharmaceuticals USD 164.49M 41.5M Jun/2026
Anika Therapeutics USD 292K 2.62M Dec/2025
Arrowhead Research USD -194.28M 61.55M Jun/2026
AstraZeneca USD 2.51B 573M Jun/2026
Bristol-Myers Squibb USD 3.32B 640M Jun/2026
Eli Lilly USD 7.1B 301M Jun/2026
Enanta Pharmaceuticals USD -22.29M 93.76M Dec/2024
Halozyme Therapeutics USD 229.91M 79.86M Jun/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Insmed USD -13.24M 150.32M Jun/2026
J&J USD 210M 5.32B Sep/2026
Lexicon Pharmaceuticals USD -15.53M 2.76M Dec/2025
Ligand Pharmaceuticals USD 48.51M 61.85M Jun/2026
Merck USD -1.34B 2.9B Jun/2026
Minerva Neurosciences USD 1.44M 21.07M Dec/2024
Moderna USD -1.34B 517M Mar/2026
Novartis USD 3.16B 747M Mar/2026
Pfizer USD -248M 2.94B Jun/2026
PTC Therapeutics USD -2.81M 132.16M Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Sanofi EUR 343M 1.27B Jun/2026
Takeda JPY 113.2B 137.52B Jun/2026
Teva Pharmaceutical Industries USD -576M 945M Jun/2026
Ultragenyx Pharmaceutical USD -185M 56M Mar/2026
Vanda Pharmaceuticals USD -18.9M 13.58M Dec/2024
Veracyte USD 25.49M 3.22M Jun/2026